Press releases

Judgment entered in favor of Guidant and its former directors/officers

Data was presented at SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago

Results from TAXUS IV and V randomized clinical trials favor DES compared to bare-metal stents

At two years, Company's TAXUS® and PROMUS™ Stents demonstrate positive and similar outcomes

Sale is the latest example of Company's commitment to realigning its cost structure; overall goal is to strengthen Boston Scientific for the future

Two-year outcomes confirm the favorable results seen in previous clinical trials

One-year pooled ARRIVE data showed similarly low rates of stent-related cardiac death, myocardial infarction, stent thrombosis, and major cardiac events across the two patient subsets

Presentations to include clinical data for the TAXUS® paclitaxel-eluting coronary stent in a variety of high-risk patient populations

A live webcast and replay of the March 18 session will be available. Learn how to tune in

ACUITY® Spiral lead offers flexibility for placement in small, medium and large veins

Forty implants of COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN™ implantable cardioverter defibrillator (ICD) performed in 14 hospitals in six countries

Jay J. Schnitzer, M.D., Ph.D. to join Company's Clinical Sciences organization effective March 24

Approvals include CONFIENT™ ICD, LIVIAN™ CRT-D and upgraded LATITUDE® Patient Management System

Completes Company's previously announced plans to divest five non-strategic businesses

Company plans to seek to overturn patent infringement lawsuit verdict in post-trial motions

PROENCY will provide real-world clinical data on the PROMUS™ Stent

"The turn that began last quarter continued this quarter, with strong adjusted earnings and record sales," said Jim Tobin, President and Chief Executive Officer

'Close the Gap' brings together advocates from cardiologists to coaches

A live webcast and replay of the February 6 session will be available.

NEJM article is entitled "A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications"

A live webcast and replay of the February 5 conference call will be available

CE Mark approvals are for COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN™ implantable cardioverter defibrillator (ICD)

Ruling finds the NIR® stent, formerly sold by Company, infringed one claim of a patent owned by Johnson & Johnson

Divestitures are part of ongoing efforts to simplify operating model and restore profitable growth

Company retains ownership of Pain Management business

A live webcast and replay of the January 9 session will be available

LIVIAN™ CRT-D is specifically designed to monitor heartbeats in heart failure patients and deliver small electrical impulses that may improve the heart's pumping ability

TAXUS Liberte has more CE Mark-approved indications than any other drug-eluting stent

In addition to the two sales announced today, Boston Scientific has also recently announced agreements to sell its Cardiac Surgery, Vascular Surgery and Auditory businesses

The two stent systems are identical products; would be covered by the same FDA approval

A live webcast and replay of the December 5 session will be available

A live webcast and replay of the November 28 session will be available

Settles claims associated with product communications issued by Guidant Corporation in 2005 and 2006; Company acquired Guidant last year

Integration links LATITUDE® Patient Management system to GE's Electronic Medical Record (EMR) system

Getinge Group, a global provider of healthcare equipment and systems, to buy the two businesses for cash price of $750 million

Company believes the finding of patent infringement is in error and will request the judge to overturn it

Dr. Keith Dawkins and Dr. Takahiro Uchida to join the Company

Studies evaluated the effectiveness of stenting with embolic protection for patients at high risk for carotid endarterectomy (CEA), the surgical treatment for carotid artery disease

TAXUS IV study demonstrates long-term safety and efficacy of TAXUS drug- eluting stent compared to bare-metal stent

TAXUS ATLAS studies also reinforce deliverability of TAXUS® Liberte® drug-eluting stent in long lesions and small vessels

One-year results from the SPIRIT III trial included an updated analysis of 1,002 patients with coronary artery disease

Data showed continued low incidences of adverse events and repeat revascularization through two years in complex patients

"The quarter represented a turn for us, with a number of positive developments," said Jim Tobin, President and Chief Executive Officer

Approximately 2,300 positions to be eliminated worldwide

Schedule of Company events for the Cardiovascular Research Foundation's (CRF) 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium

CE Mark for CONFIENT™ implantable cardioverter defibrillator (ICD) represents first Boston Scientific-branded cardiac rhythm management device to treat sudden cardiac death

A live webcast and replay of the October 19 conference call will be available

Data reflects the experience from the first 15,000 patients monitored wirelessly on the LATITUDE® Patient Management System

With the election of Mr. Elliott, the Boston Scientific Board increases to 15 members

Analysis of TAXUS II, IV, V and VI trials found paclitaxel-eluting stents had similar clinical outcomes in women and men, despite women’s higher risk profile